Evidence map›Paper›PMID 42801010›Full record

ArticleJournal of hepatocellular carcinoma2026

miR-139-5p Targets CENPM to Suppress EMT and Malignant Progression of Hepatocellular Carcinoma via Regulating the Akt/mTOR Pathway and β-Catenin Nuclear Translocation.

Aihui Fan, Xiaomin Zhang, Hongjing Cui, Xianling Gong, Zhanping Gou, Chong Yan, Yanfei Guan, Shengchun Wang, Jingyi Zheng, Wanyi Li and 2 more

Abstract read
In one paragraph

Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Aihui Fan *Dongguan Key Laboratory of Stem Cell and Regenerative Tissue Engineering, School of Basic Medical Sciences, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.ORCID 0000-0001-8809-7932
Xiaomin Zhang *Dongguan Key Laboratory of Stem Cell and Regenerative Tissue Engineering, School of Basic Medical Sciences, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.
Hongjing Cui *Department of Histology and Embryology, School of Basic Medical Sciences, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.
Xianling GongDepartment of Traditional Chinese Medicine, School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.
Zhanping GouDepartment of Traditional Chinese Medicine, School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.
Chong YanDepartment of Traditional Chinese Medicine, School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.
Yanfei GuanDongguan Key Laboratory of Stem Cell and Regenerative Tissue Engineering, School of Basic Medical Sciences, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.
Shengchun WangDepartment of Pathology, School of Basic Medical Sciences, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.
Jingyi ZhengDongguan Key Laboratory of Stem Cell and Regenerative Tissue Engineering, School of Basic Medical Sciences, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.
Wanyi LiDongguan Key Laboratory of Screening and Research of Anti-Inflammatory Ingredients in Chinese Medicine, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.
Linghui DianDepartment of Traditional Chinese Medicine, School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.
Jilun ChengDepartment of Traditional Chinese Medicine, School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong, People's Republic of China.ORCID 0009-0002-4679-9017

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study aims to screen key miRNA/mRNA axes associated with hepatocellular carcinoma (HCC), and then conduct functional validation and mechanistic exploration, thereby offering novel clues for screening HCC-targeted therapeutic candidates. Methods: Bioinformatics analysis was performed to identify key HCC-related miRNA/mRNA axes. The direct interaction between hsa-miR-139-5p and centromere protein M (CENPM) was verified via a dual-luciferase reporter (DLR) assay. We carried out colony formation, Transwell and in vivo xenograft assays to validate the biological functions of the hsa-miR-139-5p/CENPM axis. The underlying mechanism of this axis was further explored via in vitro cellular experiments. The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) cohort was used for prognostic evaluation of this axis. Results: Six key HCC-related miRNA/mRNA regulatory axes were screened out. The hsa-miR-139-5p/CENPM axis was selected for further validation. DLR assay confirmed that hsa-miR-139-5p directly targeted CENPM. Sole overexpression of hsa-miR-139-5p significantly downregulated CENPM protein levels, and suppressed in vitro cell colony formation, migration and invasion, as well as in vivo growth of subcutaneous HCC xenografts. Notably, simultaneous overexpression of CENPM could fully rescue the tumor-suppressive phenotypes induced by hsa-miR-139-5p overexpression. In contrast, sole overexpression of CENPM markedly promoted HCC cell malignant behaviors and subcutaneous xenograft growth, while concurrent transfection of hsa-miR-139-5p could attenuate these oncogenic effects driven by CENPM overexpression. Mechanistically, hsa-miR-139-5p restrained the activation of the Akt/mTOR pathway and inhibited nuclear translocation of β-catenin to suppress epithelial-mesenchymal transition (EMT) by targeting CENPM in HCC cells. The hsa-miR-139-5p Conclusion: hsa-miR-139-5p targeted CENPM to suppress EMT and malignant progression of HCC via regulating the Akt/mTOR pathway and β-catenin nuclear translocation. The combined expression pattern of hsa-miR-139-5p and CENPM correlated significantly with HCC patient prognosis. Our findings offer new evidence for HCC prognostic stratification and targeted intervention candidate screening.

Indexed as

Akt/mTOR pathwaybioinformatics analysisCENPMEMThepatocellular carcinomahsa-miR-139-5p

Identifiers

PMID42801010
PMCPMC13615298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.